Alpha Cognition Inc. $ACOG

What the company doesAI summary of filing

Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, primarily Alzheimer's disease. The company's main revenue-generating product is ZUNVEYL (benzgalantamine), an acetylcholinesterase inhibitor oral tablet that received FDA approval on July 26, 2024, for mild-to-moderate Alzheimer's disease and launched commercially on March 19, 2025. The company makes money by selling ZUNVEYL directly in the United States through a specialty sales force targeting long-term care facilities, with a wholesale acquisition cost of $820 per month, and through international licensing partnerships such as an exclusive agreement with CMS International for distribution in Asia, Australia, and New Zealand. The company also has additional pre-clinical stage programs including ZUNVEYL combined with memantine for moderate-to-severe Alzheimer's disease, sublingual formulations of benzgalantamine, and other neurodegenerative disease candidates including programs for ALS and spinal muscular atrophy. [10-K 2026-03-31]

Segments: ZUNVEYL (benzgalantamine) delayed release oral tablet, ZUNVEYL + memantine combination therapy, ALPHA-1062 sublingual formulation, Progranulin-based programs (ALPHA-0602, ALPHA-0702, ALPHA-0802)